糖尿病的干细胞治疗
糖尿病对健康寿命和寿命有长期且可能严重的影响,并给全球医疗、经济和社会带来巨大负担。现有药物无法妥善解决功能性胰腺β细胞最终缺乏的问题,而死者供体胰岛细胞移植的需求远超供应。过去十年在从人类多能干细胞衍生胰腺胰岛样细胞方面取得了实质性的科学和临床进展,本文批判性综述了科学进展、临床试验及监管考量,探讨其成为糖尿病治疗下一项细胞疗法突破的可能性。
要点
- 现有糖尿病药物不能妥善解决功能性胰腺β细胞缺乏的问题。
- 死者供体胰岛细胞移植是胰岛素依赖型1型糖尿病的既定疗法,但需求远超供应。
- 过去十年从人类多能干细胞衍生胰腺胰岛样细胞取得实质的科学和临床进展。
核心结论
- 从人类多能干细胞衍生胰腺胰岛样细胞可能为供应问题提供潜在无限解决方案,并开启糖尿病细胞治疗新时代。
- 人类干细胞来源的胰腺胰岛样细胞要成为糖尿病治疗的下一项细胞疗法突破,仍需克服多种监管考量。
研究设计与样本
- 本文为批判性综述,审视科学进展、临床试验及监管考量。
主要发现
- 过去十年在从人类多能干细胞衍生胰腺胰岛样细胞方面取得了实质的科学和临床进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetes has long-term, potentially severe implications for healthspan and lifespan and imposes an immense burden on global healthcare, the economy and society. Although a repertoire of medications is available to treat diabetes, these do not properly address the eventual lack of functional pancreatic beta cells that are needed to secrete insulin and maintain glucose homeostasis. Human islet cell transplantation from deceased donors is an established treatment for insulin-requiring type 1 diabetes, but demand outstrips supply. Substantial scientific and clinical progress has occurred in the last decade toward deriving pancreatic islet-like cells from human pluripotent stem cells, suggesting a potentially limitless solution to the supply issue and a new era in cell therapy for diabetes. Here, we critically review the scientific advances, the clinical trials and the various regulatory considerations that will need to be overcome for human stem cell-derived pancreatic islet-like cells to become the next cell therapy breakthrough for diabetes treatment.
引用
- Chen JT, Dadheech N, Tan EHP, et al. Stem cell therapies for diabetes. Nat Med. 2025. PMID: 40579550. doi:10.1038/s41591-025-03767-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。